


AD-A241 308



## PUBLICATION REPORT

91-12592



1010

98/89-90

EVALUATION OF UNICEF/ARAB REPUBLIC OF EGYPT/WHO  
SCHISTOSOMIASIS CONTROL PROJECT IN BEHEIRA GOVERNORATE

BY

Harrison C. Spencer, Ernesto Ruiz-Tiben,  
Nashy S. Mansour and Barnett I. Cline

Document has been approved  
for release and sale; its  
distribution is unlimited.

U.S. NAVAL MEDICAL RESEARCH UNIT NO. 3  
(CAIRO, ARAB REPUBLIC OF EGYPT)

FPO NEW YORK 09527

91 10 4 156

# REPORT DOCUMENTATION PAGE

1a REPORT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>			1b RESTRICTIVE MARKINGS		
2a SECURITY CLASSIFICATION AUTHORITY			3 DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; Distribution is unlimited.		
2b DECLASSIFICATION/DOWNGRADING SCHEDULE					
4 PERFORMING ORGANIZATION REPORT NUMBER(S) <b>98/89-90</b>			5 MONITORING ORGANIZATION REPORT NUMBER(S)		
6a NAME OF PERFORMING ORGANIZATION <b>U.S. Naval Medical Research Unit No. 3</b>		6b OFFICE SYMBOL (If applicable) <b>NAVMEDRSCH THREE</b>	7a NAME OF MONITORING ORGANIZATION		
6c ADDRESS (City, State, and ZIP Code) <b>PSC 452, Box 5000 FPO, AE 09835-0007</b>			7b ADDRESS (City, State, and ZIP Code)		
8a NAME OF FUNDING/SPONSORING ORGANIZATION <b>Naval Medical Re- search and Development Command</b>		8b OFFICE SYMBOL (If applicable) <b>NAVMEDRSCH DEVCOM</b>	9 PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8c ADDRESS (City, State, and ZIP Code) <b>National Naval Medical Center Building 1, Tower 12 Bethesda, MD 20889-5044</b>			10 SOURCE OF FUNDING NUMBERS		
			PROGRAM ELEMENT NO <b>61102A</b>	PROJECT NO <b>3M1611- 02BS13</b>	TASK NO <b>AK</b>
11 TITLE (Include Security Classification) <b>Evaluation of UNICEF/Arab Republic of Egypt/WHO Schistosomiasis Control Project in Beheira Governorate. (UNCLASSIFIED).</b>					
12 PERSONAL AUTHOR(S) <b>Spencer, Harrison C.*, Ruiz-Tiben, Ernesto*, Mansour, Noshay S. and Cline, Barnett I.+</b>					
13a TYPE OF REPORT		13b TIME COVERED FROM _____ TO _____		14 DATE OF REPORT (Year, Month, Day) <b>1989</b>	
15 PAGE COUNT <b>7</b>					
16 SUPPLEMENTARY NOTATION <b>Published in: Am. J. Trop. Med. Hyg., 42(5):441-448, 1990; Acc. No. 1616.</b>					
17 COSATI CODES			18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number) <b>Schistosomiasis Control; <u>S. mansoni</u>; <u>S. haematobium</u>; Praziquantel; Treatment; School children; Egypt.</b>		
FIELD	GROUP	SUB-GROUP			
19 ABSTRACT (Continue on reverse if necessary and identify by block number) <b>We evaluated the UNICEF/Government of Egypt/WHO Schistosomiasis Control project in 2 districts of Beheira Governorate of the Nile Delta during 3 weeks in February 1988. The project, begun in 1983, was focused on reducing prevalence, intensity, and morbidity due to schistosomiasis by providing diagnosis and treatment with praziquantel to schoolchildren. School were visited twice. Following the completion of the school surveys, the program was extended into the community. Chemotherapy was delivered by mobile and static teams. The evaluation indicated that, with respect to accuracy of diagnosis, record-keeping, and coverage of targeted populations, project tasks were performed exceedingly well by highly motivated, well-supervised mobile teams. Static teams in rural health centers were less successful in providing diagnosis and chemotherapy to village populations. We resurveyed 6 randomly selected schools to assess the impact of chemotherapy. Overall, the prevalence of <u>Schistosoma mansoni</u> infection was reduced from 60.3% to 24.8% between the first and second surveys (~1 year apart) and was still lower (41.1%) than initial levels up to 3 years after</b>					
20 DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21 ABSTRACT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>		
22a NAME OF RESPONSIBLE INDIVIDUAL <b>Research Publications Branch</b>			22b TELEPHONE (Include Area Code) <b>202-284-1381</b>		22c OFFICE SYMBOL <b>R.P.B.</b>

DD FORM 1473, 84 MAR

83 APR edition may be used until exhausted  
All other editions are obsolete

SECURITY CLASSIFICATION OF THIS PAGE

☆ U.S. Government Printing Office 1986-607-044

UNCLASSIFIED

UNCLASSIFIED  
98/89-90 (Contd.)


19. the last treatment with praziquantel. The percentages of those with  $\geq 34$  S. mansoni eggs/slide using the Kato-Katz technique showed a marked and prolonged decrease (17.1% to 0.3% to 2.2%). The prevalence of S. haematobium infection dropped from 37.6% to 5.5% and was still 9.9% at the time of the evaluation. The percentages of those with  $\geq 50$  S. haematobium eggs/10 ml urine dropped less dramatically (17% to 4.4% to 11.9%). Mobile teams conducting vigorous chemotherapy programs targeted at schoolchildren can have long-lasting benefits in terms of prevalence and intensity.

12. \* Parasitic Diseases Branch, Division of Parasitic Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA.

+ Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.

UNCLASSIFIED

# DISCLAIMER NOTICE



THIS DOCUMENT IS BEST QUALITY AVAILABLE. THE COPY FURNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH DO NOT REPRODUCE LEGIBLY.

## EVALUATION OF UNICEF/ARAB REPUBLIC OF EGYPT/WHO SCHISTOSOMIASIS CONTROL PROJECT IN BEHEIRA GOVERNORATE

HARRISON C. SPENCER, ERNESTO RUIZ-TIBÉN, NOSHAY S. MANSOUR  
AND BARNETT L. CLINE

Centers for Disease Control, Atlanta, Georgia, U.S.; Naval Medical Research Unit No. 3, Cairo,  
Egypt; Tulane University School of Public Health, New Orleans, Louisiana

**Abstract.** We evaluated the UNICEF/Government of Egypt/WHO Schistosomiasis Control project in 2 districts of Beheira Governorate of the Nile Delta during 3 weeks in February 1988. The project, begun in 1983, was focused on reducing prevalence, intensity, and morbidity due to schistosomiasis by providing diagnosis and treatment with praziquantel to schoolchildren. Schools were visited twice. Following the completion of the school surveys, the program was extended into the community. Chemotherapy was delivered by mobile and static teams. The evaluation indicated that, with respect to accuracy of diagnosis, record-keeping, and coverage of targeted populations, project tasks were performed exceedingly well by highly motivated, well-supervised mobile teams. Static teams in rural health centers were less successful in providing diagnosis and chemotherapy to village populations. We resurveyed 6 randomly selected schools to assess the impact of chemotherapy. Overall, the prevalence of *Schistosoma mansoni* infection was reduced from 60.3% to 24.8% between the first and second surveys (~1 year apart) and was still lower (41.1%) than initial levels up to 3 years after the last treatment with praziquantel. The percentages of those with  $\geq 34$  *S. mansoni* eggs/slide using the Kato-Katz technique showed a marked and prolonged decrease (17.1% to 0.3% to 2.2%). The prevalence of *S. haematobium* infection dropped from 37.6% to 5.5% and was still 9.9% at the time of the evaluation. The percentages of those with  $\geq 50$  *S. haematobium* eggs/10 ml urine dropped less dramatically (17% to 4.4% to 11.9%). Mobile teams conducting vigorous chemotherapy programs targeted at schoolchildren can have long-lasting benefits in terms of prevalence and intensity.

Schistosomiasis is one of the most important public health problems affecting Egyptians, especially inhabitants of the rural farming communities of the Nile Delta.<sup>1</sup> Currently, 15-30% of Egypt's population of ~50 million is infected with *Schistosoma mansoni*, *S. haematobium*, or both, depending on the estimate used; the disease causes significant morbidity and mortality.<sup>1-4</sup> In 1983, UNICEF, WHO, and the Government of Egypt agreed to initiate a schistosomiasis control project in 2 highly endemic districts of the Beheira Governorate in the Nile Delta. Peak prevalence and intensity (heavy infections) rates of schistosomiasis in Egypt occur in school-age children.<sup>1,2</sup> The program attempted to provide diagnosis and treatment with praziquantel to all children attending school. What follows is an evaluation of the project, carried out in February 1988.

### MATERIALS AND METHODS

#### Project description

The project is presented in detail elsewhere.<sup>5</sup> Diagnosis and treatment of schistosomiasis were

accomplished by mobile and static teams. Four mobile teams visited schools and communities; each consisted of a medical doctor, 2 laboratory technicians, 2 clerks, 1 nurse, 2 laboratory workers, and 1 driver. Mobile teams were selected and trained especially for the project; their only tasks were to diagnose and treat schistosomiasis. In contrast, no new personnel were hired for the static teams, and they had a wide range of other responsibilities in addition to those of the project. The static teams consisted of the personnel assigned to the rural health units and were generally comprised of 1 doctor, 1 laboratory technician, 1 clerk, and 1 nurse. Static teams provided diagnosis and treatment to people who came to the rural health units.

Beginning in 1982, all schools in the Abu El Matameer district (population ~160,000, including 31,000 schoolchildren) and Abo Homos district (population ~247,000, including 47,000 schoolchildren) were visited by a mobile team. Each child was asked to submit a urine and a stool specimen. These were examined for schistosomiasis on site using the Kato-Katz thick

smear method for stool specimens<sup>7</sup> and a syringe-Nytrel filter technique for urine samples.<sup>8</sup> Infected children were weighed and treated with praziquantel, 40 mg/kg body weight. The teams returned to the school until all children absent at the initial visit were examined. This procedure was repeated twice in each school with an interval of ~1 year between visits.

Diagnosis and treatment for schistosomiasis were provided to community members other than schoolchildren. During the school surveys, community members were encouraged to come to rural health centers where they were examined and, if necessary, treated by the static teams. When the school surveys were completed, the mobile teams extended the control program into the village councils, where they systematically examined the population, excluding only children examined in the schools. Village councils are the major subdivisions of districts. They include a main village, satellite villages, and small groups of households. Main villages have a rural health center and a school. Satellite villages have no school, no rural health center, and usually have a population < 1,000.

#### *Evaluation process*

The evaluation was carried out in Egypt from 29 January through 17 February 1988 and included data collection in the project districts and preparation of a report. The terms of reference specified an evaluation of how well the program was implemented by examining the specific tasks carried out, determination of the impact of praziquantel on the prevalence and intensity of *S. mansoni* and *S. haematobium* infection in schoolchildren and in the community, identification of problems occurring in implementing the program as planned, and consideration of the relevance of this control intervention to schistosomiasis control in the Nile Delta region of Egypt.

#### *Validation of diagnosis*

*S. mansoni.* To determine the validity of the diagnosis of *S. mansoni* by mobile teams, results from stool specimens examined by these teams were compared with those from a reference laboratory. Mobile teams rather than static teams were evaluated because they carried out >80%

of the stool and urine examinations performed during the project. The U.S. Naval Medical Research Unit No. 3 (NAMRU-3) Parasitology Division participated as the reference laboratory.

One hundred and fifty-seven stool specimens were randomly selected from among those collected during the surveys in schools. Additionally, one known *S. mansoni*-negative stool specimen was obtained from a member of the evaluation team. Each specimen was divided into 2 equal portions; 1 was examined by the mobile team and the other by the reference laboratory. Specimens were transferred to the reference laboratory by automobile and examined the next day. The results of the readings from the 2 groups were then compared.

To compare accuracy of microscopic diagnosis, thick smears were prepared from each portion using the Kato-Katz technique. Thick smears from portions processed and examined first by each mobile team were recoded by the evaluation team and sent to the reference laboratory and vice versa. Neither the reference laboratory nor the mobile teams knew the results of the other nor could they determine which 3 slides came from the same portion. Egg counts obtained from the triplicate smears were averaged, and these averages were transformed to logarithms. The geometric mean number of eggs/g feces (epg) obtained from readings by the mobile teams and by the reference laboratory were compared using Student's *t*-test.

*S. haematobium.* The Nytrex-filtration technique used by the mobile teams in examining urine samples for *S. haematobium* was observed. On randomly selected specimens, 1 of the team members examined the filter under a microscope to verify the accuracy of the diagnosis.

#### *Data recording and analysis*

The results of the stool and urine examinations were recorded by the microscopists. These results were later transferred to survey forms containing additional patient information, including name, age, sex, weight, and the number of praziquantel tablets given. A sample of 100 microscopy records in each of 6 schools (see below) were examined to ascertain how stool and urine egg counts for specific individuals corresponded with those on the survey forms.

Hand-tabulated data summaries (for all sur-

TABLE 1

Concordance of *Schistosoma mansoni* diagnosis performed by mobile teams of the UNICEF-Government of Egypt WHO Schistosomiasis Control Project and NAIKUA Parasitology Laboratory using a single Kato-Katz thick smear

		Aliquots examined by reference laboratory		
		Positive	Negative	Total
Aliquots examined by mobile teams	Positive	90	5	95
	Negative	6	57	63
	Total	96	62	158

veys) from each of the 6 schools and 4 villages selected in the evaluation (see below) were checked by the evaluation team. All individual records (found on the survey forms) included in these summaries were entered into a computer, analyzed, and compared with hand-tabulated data.

Coverage in the school surveys was assessed by obtaining records of the number of children registered in the school at the time of each survey and comparing those with the records from the mobile teams. Population estimates for main and satellite villages were obtained and compared with the records of the mobile teams. Records from selected static teams in the rural health centers were reviewed to estimate population coverage achieved by the static teams.

#### Impact on schistosomiasis

**Schools.** Primary schools were stratified by prevalence of schistosomiasis (both *S. mansoni* and *S. haematobium*) at the time of the initial survey (<50%, 50–89%, or ≥90%). One school from each group was randomly selected in each district, for a total of 6 schools. During the evaluation period, these 6 schools were visited by the mobile teams. All children were examined for schistosomiasis and, if necessary, treated exactly as was done in the earlier surveys.

**Cohort.** Records of previous surveys were used to identify by name children examined during each survey, including the evaluation survey; a cohort of 530 children could be identified from 5 schools (in 1 school a cohort could not be identified). The results from each survey were then compared.

**Community.** To determine the impact of schis-

tosomiasis on the community, satellite villages were stratified according to the time interval since the previous survey (<1 year or ≥1 year). One satellite village in each group was surveyed in each district during the evaluation period, for a total of 4 villages. Although the mobile teams systematically examined the total population, including those living in larger villages, satellite villages were selected because their size (~1,000 inhabitants) made it possible to re-examine the residents during the evaluation.

## RESULTS

### Validation of diagnosis

***S. mansoni.*** One hundred fifty-eight specimens were processed and examined by both a mobile team and the reference laboratory. The concordance of results based on a single Kato-Katz smear is presented in Table 1. Agreement was excellent; 90 specimens (57%) were positive by both the team and the reference laboratory, and 57 specimens (36%) were negative in both. In only 11 instances (7%) was there disagreement, and the divergent results were equally distributed. The percentages of discordant results are not statistically significant.

Egg counts obtained by reading triplicate smears were also very similar. The mean epq was 68.9 for slides examined by the mobile teams and 24.9 for those examined by the reference laboratory. These differences were not statistically significant.

***S. haematobium.*** The proportion of infection caused by *S. haematobium* in the school survey was much lower than that caused by *S. mansoni* (Table 2). The syringe filtration technique used by each of the mobile teams was observed and found to be performed correctly. However, Lugol's iodine solution was not used to stain eggs in the specimens prepared during the observation period. Spot checks of positive and negative filters by the evaluation team gave results identical to those of the mobile teams.

### Data recording and analysis

All egg counts had been accurately transcribed from the microscopy records to the survey and treatment forms. Computer-generated data sum-

Page 444 Missi'



tion in the satellite villages was reduced even in the villages surveyed 1 year later (Table 3). In the village (C) where intensity was high initially, it was also reduced. The prevalence of *S. haematobium* infection was low in these 4 randomly selected satellite villages. However, in the Lyf-lape (D) where *S. haematobium* infection was

10%, both prevalence and intensity were significantly reduced at the time of the second survey 7 months later.

#### DISCUSSION

The concordance between laboratory results obtained by the mobile teams and those of the reference laboratory was excellent. The demonstrated ability of the mobile teams to diagnose schistosomiasis correctly attests to the quality of training and supervision the teams received and lends credence to the data suggesting that the program had a significant impact on the prevalence and intensity of schistosomiasis. It was impossible in the time available to evaluate the diagnostic accuracy of the static teams; there were ~150 rural health centers in the 2 districts, each with a team. However, static teams performed <20% of the total examinations.\* The ability to diagnose schistosomiasis under field conditions is necessary for chemotherapy-based control strategies.\* These data support those from other areas demonstrating that schistosomiasis can be accurately diagnosed and treated under field conditions.\*<sup>11</sup>

Coverage was high in the schools, largely because the schools were revisited until all students were examined. Cooperation was excellent among those attending on any given day; virtually every child provided a stool and urine sample. However, in Egypt and elsewhere, some school-age children do not attend school and thus may not be reached by such programs. In this study, girls were absent from school more often than were boys. Additionally, emigration of students before follow-up examinations and refusal to take treatment could also affect results. In some studies, treatment compliance was less and emigration highest in older (>15 years) children.<sup>12</sup> It is unlikely that many schistosomiasis control programs could expend the necessary resources for multiple visits to achieve the degree of coverage attained in this project.

Population coverage by the static teams based in rural health centers was low. The static teams

were smaller than the mobile teams (4 persons instead of 9), they had many other responsibilities in the rural health units, the turnover of personnel (especially physicians) was rapid, and physicians were only available part-time. There was no effective campaign to encourage people to go to rural health units for diagnosis and treatment of schistosomiasis. Indeed, most people expected that the mobile teams would move into the community after the school surveys were finished. Many villagers preferred to await the arrival of mobile teams. However, in future interventions it would be difficult, if not impossible, to ignore the potential contribution to schistosomiasis control of the ~1,300 rural health centers (potential static teams) in the Nile Delta, which are within convenient reach of the vast majority of the rural inhabitants. An important issue for future planning is how and to what extent these obstacles to the use of rural health units can be overcome.

There was a persistent reduction in the prevalence and intensity of schistosomiasis infection in schoolchildren and in the general population as many as 3 years after treatment with praziquantel. This effect was most marked with *S. haematobium* infections, in which both the prevalence and intensity remained lower than baseline levels. The prevalence of *S. mansoni* infections increased towards pre-treatment values, while the intensity remained low. Although the efficacy of chemotherapy in reducing sequelae of schistosomiasis over the long term was not measured, the UNICEF Project achieved its goal of reducing schistosome egg burdens in the target population. These results are consistent with those from other research projects in corroborating that chemotherapy reduces high worm burdens (and thus egg excretion), the major risk factor for disease, for relatively long periods of time.<sup>4,12-18</sup> In only a few areas, mass chemotherapy has had little effect on morbidity and intensity of infection, possibly because of very high infection rates.<sup>19</sup>

Transmission of *S. haematobium* (in contrast to *S. mansoni*) was low, as evidenced by the sustained reduction in infection prevalence. There is no evidence that treatment with praziquantel prevents reinfection or decreases selectively the rate of reinfection with *S. haematobium*. Thus, if the results were exclusively caused by the drug, there should have been a similar response with *S. mansoni*. When resistance to reinfection after

Accession For		
NTIS	CRA&I	<input checked="" type="checkbox"/>
DTIC	TAB	<input type="checkbox"/>
Unannounced		<input type="checkbox"/>
Justification .....		
By .....		
Distribution /		
Availability Codes		
Dist	Avail. & or Special	
A-1	20	23



TABLE 3

Prevalence and intensity by survey of *S. mansoni* and *S. haematobium* infection in randomly selected villages provided population chemotherapy by months between chemotherapy and the evaluation survey

Village	No. examined		Months between surveys	Prevalence*				Intensity†			
	Survey 1	Survey 2		<i>S. mansoni</i>		<i>S. haematobium</i>		<i>S. mansoni</i>		<i>S. haematobium</i>	
				1	2	1	2	1	2	1	2
A	192	131	1	72	33	0	0	0	1	0	0
B	751	857	7	36	25	13	5	1	0	20	0
C	231	264	12	79	33	1	0	23	3	13	0
D	1,152	909	13	82	56	0	0	1	2	0	0

\* Percentage of persons infected.

† For *S. mansoni*, the percentage of infected persons with  $\geq 14$  eggs/Kato-Katz slide ( $\geq 816$  eggs), for *S. haematobium*, the percentage of infected persons with  $\geq 50$  eggs/10 ml urine.

‡ For each survey, persons were examined for the presence of schistosomes (stool and urine sample) and infected individuals were treated with praziquantel. Survey 2 was done at the time of the evaluation.

treatment of *S. haematobium* and *S. mansoni* has been demonstrated, older children (>10 years) appear to be more resistant, probably due to acquired immunity; this would not have affected the age groups in this evaluation (the majority were 6–9 years).<sup>20,21</sup> However, this may have been a factor in the more dramatic reductions observed in the 4 satellite villages evaluated. There was no evidence that selective treatment for *S. haematobium*, e.g., metrifonate, was given between surveys.

This degree of sustained low *S. haematobium* transmission following chemotherapy has rarely been observed and may be, in part, due to the reduced risk of reintroduction of the parasite because of the background of reduced prevalence in the region as well as the excellent chemotherapy coverage achieved in the schools.<sup>22</sup> During the past 10 years, the work of numerous investigators has confirmed that profound changes have occurred in the Nile Delta in the epidemiology of schistosomiasis, namely, a striking decrease in the distribution and overall prevalence of *S. haematobium*.<sup>23,24</sup> During the 1950s, the prevalence of *S. haematobium* was 60–70%, but by 1984 it was only 7% in a sample of villages from 70 of the 71 districts in the 8 governorates of the Nile Delta.<sup>25</sup> An equally remarkable decrease in the population levels of *Bulinus truncatus*, the vector snail, was associated with this decrease. The decrease in *B. truncatus* may be related to ecological alterations caused by the long-term process of damming the Nile.<sup>26</sup>

The evaluation demonstrated that this school-based chemotherapy program in Egypt was effective. Control programs targeted to schoolchildren are relatively easy to organize and administer. Since children have the highest

prevalence and intensity of schistosomiasis infection in Egypt,<sup>1,2</sup> diagnosis and treatment of children should reduce morbidity. Similar studies in other countries have also demonstrated that chemotherapy to schoolchildren is a practical strategy to reduce the prevalence, intensity, and associated morbidity of infection with *S. haematobium* and *S. mansoni*.<sup>12,15,27</sup> It is clear that praziquantel is not only a safe and effective drug against *S. mansoni*, but that it is well-accepted in village or school-based programs despite the relatively common occurrence of transient, generally mild, side effects. In this project, refusal of the drug was extremely rare. Indeed, once programs were initiated in communities, there was widespread public demand for diagnosis and chemotherapy. A number of issues remain to be clarified, however. It is not known how cost-effective this strategy is in relation to other ways of providing diagnosis and treatment. How frequent it is necessary to re-treat is not known, nor, correspondingly, is there sufficient evidence to indicate the long-term impact on morbidity if reinfection occurs.

Despite the fact that selected population chemotherapy may not interrupt transmission of *S. mansoni*, the intensity of infection in the population is reduced for relatively long periods of time. Although prevalence may increase rapidly after chemotherapy as a consequence of reinfection, the intensity of infection (and the morbidity) tends to remain low for periods of  $\geq 1$  year. As seen in Table 2, the intensity of *S. mansoni* infection in schoolchildren remains  $< 1/2$  that of pre-treatment levels some 3 years after chemotherapy. The obvious operational and financial implication of these findings is that chemotherapy coverage every 2–3 years may be effective

in reducing intensity and morbidity, thus greatly reducing program costs.

The cost of praziquantel has declined rapidly in recent years, and the trend continues. The drug is available via governmental channels at a greatly reduced cost, and in the private sector in Egypt the price is much reduced due to intense competition in the pharmaceutical industry. The rapid decline in the retail cost of praziquantel via governmental (~\$1.50 U.S. per treatment) and private (~\$3.00 per treatment) sources bring this drug within reach of most of the Egyptian population. Further reductions in drug costs are anticipated.

Adequate population coverage for diagnosis and chemotherapy of schistosomiasis may be achieved by building on the existing health network of rural health centers in the Delta and by linking their diagnostic capabilities with both private and public sources of chemotherapy. Schistosomiasis control can thus be integrated with the control of other health problems. Recent experience in the highly successful oral rehydration program in Egypt has demonstrated that the mass media can be remarkably successful in modifying health-related behavior, specifically, behavior related to acquisition of medications (e.g., oral rehydration salts). A similar program on schistosomiasis has been developed for Egyptian television. Furthermore, it has been seen that the private sector (physicians and pharmacists) can respond to these demands in a parallel fashion. The major obstacles to overcome are motivating the population to seek diagnosis (since *S. mansoni* infection is often asymptomatic) and providing reliable and convenient diagnostic services. Consideration of ways to overcome these obstacles may suggest realistic and cost-effective approaches. For example, the diagnostic capabilities of rural health centers might be greatly enhanced (in terms of accuracy and volume) through imaginative use of training, enhanced supervision, financial incentives, quality control of results, and coordination of laboratory capabilities with community needs. Also, ways to ensure diagnosis of infection in local schoolchildren could be developed. Finally, efforts to modify behavior, particularly in young children, to prevent fecal and urine contamination of canals could also be tried.

Appropriate evaluation of control programs is necessary to understand the reasons for successes and failures and to maximize the cost-effective-

ness and the benefits derived from such programs. Documentation of such interventions is important for future planning. A major issue in duplicating the approach used here in other areas is the degree to which the supervision, training, and use of mobile teams can be replicated.

**Acknowledgments:** The evaluation team thanks E. J. Lannert, UNICEF Representative, for the support received during this evaluation, and Amira El Malatway, Assistant Project Officer, UNICEF Schistosomiasis Control Project, for her extraordinary dedication and efforts in carrying out its program and in facilitating the evaluation. We are grateful for the assistance of K. E. Mott, Chief, Schistosomiasis and Other Trematode Infections, Parasitic Diseases Program, World Health Organization, Geneva, Switzerland. We also thank Said El Makawy, Director General of Health, Beheira Governorate, and Saleh El Hak, Undersecretary of Health, Ministry of Health, Arab Republic of Egypt, for their interest and advice. The project and the evaluation could not have been done without the efforts and support of the late Nagy Lashine, Medical Officer Abo Homos District, and the late Ahmed El Habashy, Medical Officer Abu El Matameer District. Their dedication to public health and their efforts to improve the quality of life for the people in their districts were examples for all with whom they came in contact.

**Authors' addresses:** Harrison C. Spencer and Ernesto Ruiz-Fibén, Parasitic Diseases Branch, Division of Parasitic Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, Atlanta, GA 30333. Noshv S. Mansour, U.S. Naval Medical Research Unit No. 3, Cairo, Egypt. Barnett L. Chene, Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, 1501 Canal Street, New Orleans, LA 70112.

**Reprint requests:** Harrison C. Spencer, Parasitic Diseases Branch, Division of Parasitic Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, Mailstop 1-13, 1600 Clifton Road NE, Atlanta, GA 30333.

#### REFERENCES

1. Abdel-Wahab MF, 1982. *Schistosomiasis in Egypt*. Boca Raton, FL: CRC Press, 237. UI:8105152
2. Doumenge JP, Mott KE, Cheung C, Villenave D, Chapuis O, Perrin MF, Reaud-Thomas G, 1987. *Atlas of the global distribution of schistosomiasis*. Geneva: World Health Organization; France: Presses Universitaires de Bordeaux.
3. Kessler PN, Southgate BA, Klumpp RK, Mahmoud M, Remstrand LG, Saleh LI, 1987. Report of an independent evaluation mission on the National Bilharzia Control Program, Egypt, 1985 (abridged version). *Trans R Soc Trop Med Hyg (Suppl)* 81: 1-57. UI:87293251

4. World Health Organization, 1985. Control of schistosomiasis: report of a WHO expert committee. *WHO Tech Rep Ser* 228: 1-113. UI: 8703452
5. El Alamy MA, Cline BL, 1977. Prevalence and intensity of *Schistosoma haematobium* and *S. mansoni* infection in Qalyub, Egypt. *Am J Trop Med Hyg* 26: 470-472. UI:77199595
6. El Malatawy A, Habashi A, Lashine N, Mott KE, 1990. A UNICEF Arab Republic of Egypt WHO Schistosomiasis Control Project in Beheira Governorate, Egypt. *Bull World Health Organ* (in press).
7. Katz N, Chaves A, Pellegrino J, 1972. A simple device for quantitative stool thick-smear technique in *Schistosomiasis mansoni*. *Rev Inst Med Trop Sao Paulo* 14: 397-400. UI:73095320
8. Mott KE, 1982. A reusable polyamide filter for diagnosis of *Schistosoma haematobium* infection by urine filtration. *Bull Soc Pathol Exot* 76: 101-104. UI:83180587
9. Sleight AC, Hoff R, Mott KE, Maguire JH, da Franca Silva JF, 1986. Manson's schistosomiasis in Brazil: 11-year evaluation of successful disease control with oxamniquine. *Lancet* i: 635-637. UI:86145926
10. Brankmann OK, Werler C, Traore M, Doumbia S, Diarra A, 1988. Experiences with mass chemotherapy in the control of schistosomiasis in Mali. *Trop Med Parasitol* 39: 167-174. UI: 89018999
11. Sukwa TY, Boatin BA, Wurapa FK, 1988. A three year follow-up of chemotherapy with praziquantel in a rural Zambian community endemic for schistosomiasis mansoni. *Trans R Soc Trop Med Hyg* 82: 258-260. UI:89045067
12. King CH, Lombardi G, Lombardi C, Greenblatt R, Hodder S, Kinyanjui H, Ouma J, Odiambo O, Bryan PJ, Muruka J, and others, 1988. Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. *Am J Trop Med Hyg* 39: 295-305. UI: 89023718
13. Mott KE, 1982. Control of schistosomiasis: morbidity-reduction and chemotherapy. *Acta Leidensia* 49: 101-111. UI:84175084
14. Jordan PD, 1985. *Schistosomiasis: the St. Lucia project*. Cambridge: Cambridge University Press. UI:8500616
15. el Tayeb M, Dallalla AA, Kardaman MW, See R, Fenwick A, 1988. Praziquantel and oltipraz: the treatment of schoolchildren infected with *Schistosoma mansoni* and/or *Schistosoma haematobium* in Gezira, Sudan. *Am J Trop Med Parasitol* 82: 53-57. UI:88293094
16. Homerda MA, Fenwick A, DeFalla AA, Suliman S, Kardaman MW, el Tom I, Nash T, Bennett JL, 1988. Effect of antischistosomal chemotherapy on prevalence of Symmers' periportal fibrosis in Sudanese villages. *Lancet* 2: 437-440. UI:88301647
17. Mahmoud AA, Siongok TA, Ouma J, Houser HB, Warren KS, 1983. Effect of targeted mass treatment on intensity of infection and morbidity in schistosomiasis mansoni: 3-year follow-up of a community in Machakos, Kenya. *Lancet* i: 849-851. UI:83166030
18. Doehring E, Reider F, Schmidt-Ehry G, Ehrlich JH, 1985. Reduction of pathological findings in urine and bladder lesions in infection with *Schistosoma haematobium* after treatment with praziquantel. *J Infect Dis* 152: 807-810. UI: 86009766
19. Kloetzel K, Schuster NH, 1987. Repeated mass treatment of schistosomiasis mansoni: experience in hyperendemic areas of Brazil. I. Parasitological effects and morbidity. *Trans R Soc Trop Med Hyg* 81: 365-370. UI:88071639
20. Wilkins HA, Blumenthal UJ, Hagan P, Hayes RJ, Tulloch S, 1987. Resistance to reinfection after treatment of urinary schistosomiasis. *Trans R Soc Trop Med Hyg* 81: 29-35. UI:88178929
21. Butterworth AE, Capron M, Cordingley JS, Dalton PR, Dunne DW, Kariuki HC, Kimani G, Koech D, Mugambi M, Ouma JH, and others, 1985. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. *Trans R Soc Trop Med Hyg* 79: 393-408. UI:85301405
22. Wilkins HA, 1989. Reinfection after treatment of schistosome infections. *Parasitology Today* 5: 83-88.
23. Cline BL, Ruiz-Tiben E, el-Alamy MA, 1979. Schistosome patterns in Egypt. *Lancet* 2: 792. UI:80031614
24. Abdel-Wahab MF, Strickland GT, El-Sahly A, El-Kady N, Zakaria S, Ahmed L, 1979. Changing pattern of schistosomiasis in Egypt 1935-79. *Lancet* 2: 242-244. UI:79243361
25. Cline BL, Richards FO, el Alamy MA, el Hak S, Ruiz-Tiben E, Hughes JM, McNeeley DF, 1989. 1983 Nile Delta schistosomiasis survey: 48 years after Scott. *Am J Trop Med Hyg* 41: 56-62. UI: 89349607
26. Cline BL, El Alamy M, Ruiz-Tiben E, 1981. The planning of a community health model project in an area in Egypt (El Qalyub) with concomitant occurrence of *S. mansoni* and *S. haematobium*. *Arzneimittelforschung* 31: 609-612. UI: 81207452
27. Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Oduori ML, Crompton DW, 1985. Relationships of *Schistosoma haematobium*, hookworm and malarial infections and metrifonate treatment to growth of Kenyan school children. *Am J Trop Med Hyg* 34: 1109-1118. UI: 86212798